Article

Dorzolomide HCI OK for use in children

The FDA has approved Merck Human Health's dorzolomide HCI (Trusopt) ophthalmic solution 2% for use in pediatric patients. The drug is used to treat elevated IOP in patients with ocular hypertension or open-angle glaucoma.

Related Videos
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Edward Manche, MD
Related Content
Factors affecting ROP development in the 8 weeks following birth
October 24th 2024

Factors affecting ROP development in the 8 weeks following birth

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

ASU researchers tap AI to help people see more clearly
October 7th 2024

ASU researchers tap AI to help people see more clearly

Managing a changing landscape of IRD pediatric cases
May 10th 2021

Managing a changing landscape of IRD pediatric cases

Faster identification of infants at high risk of ROP by evaluating the effects of maternal and fetal vascular malperfusion
September 25th 2024

Faster identification of infants at high risk of ROP by evaluating the effects of maternal and fetal vascular malperfusion

Alcon Children’s Vision Center recipient of 10th Annual Bonnie Strickland Champion for Children’s Vision Award
Published: September 24th 2024 | Updated: September 24th 2024

Alcon Children’s Vision Center recipient of 10th Annual Bonnie Strickland Champion for Children’s Vision Award

© 2024 MJH Life Sciences

All rights reserved.